Previous 10 | Next 10 |
Recruitment completed for stage 1 of Part C of TACTI-002 trial, for patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC) Part C has been expanded to include an additional 19 HNSCC patients, creating stage 2 of Part C Follows Data Monitoring Committee (DMC) decision af...
Immutep (ASX:IMM, IMMP ) is an Australian primarily listed biotechnology company working primarily in the field of cancer immunotherapy using the Lymphocyte Activation Gene 3 (LAG-3) immune control mechanism. Frederic Triebel, the Founder and Chief Scientist at Immutep, discovered in the...
Recruitment commenced for second cohort of 6 patients at higher efti dose combined with avelumab No new safety signals in the first cohort, with 1 patient reporting a partial response More data expected to be reported in H1 CY2020 SYDNEY, Australia, Dec. 19, 2019 (GLOBE NEWSWIRE) -- I...
As of December 3, Russell 2000 Index (RUT, +7.3), which is a benchmark for small-cap stocks, is outperforming the S&P 500 (SP50, +5.2%) and Russell 3000 (RUA, +5.5%) benchmark indices in Q4 2019 (Exhibit 1). The Russell 2000 Index is a market-capitalization weighted index measuring the perfo...
SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 3116909 entitled “Antibody molecules to LAG-3 and uses thereof” by the European Pate...
Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trial Preliminary Overall Response Rate (ORR) of 41% from stage 1 1 of Part A ORR compares favourably to standard of care treatments for all comer PD-L1 NSCLC patients Twelve patients (71%) ...
Westwater Resources (NASDAQ: WWR ) +130% on receiving first shipment of graphite concentrate. More news on: Westwater Resources, Inc., Reata Pharmaceuticals, Inc., NF Energy Saving Corporation, Stocks on the move, Read more ...
Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumab Deep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B respectively Disease Control Rate of 66% of patients in each Part A and ...
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has receive...
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the ...
News, Short Squeeze, Breakout and More Instantly...
Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA ® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in first-...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...